Oncolytics Biotech Inc (ONCY NASDAQ) stock market data APIs
$1.0071
0.03(3%)
as of December 17, 2025
Try our APIs with
free plan!
Oncolytics Biotech Inc Financial Data Overview
Price chart is built with
Anychart
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Prev. Close
1.0071
Open
1.0375
High
1.0569
Low
0.9803
52 wk Range
0.3258-1.51
Market Cap
112 M
Shares Outstanding
108 M
EPS
-0.14
Beta
0.883
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Oncolytics Biotech Inc data using free add-ons & libraries
Get Oncolytics Biotech Inc Fundamental Data
Oncolytics Biotech Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -34 897 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-13
- EPS/Forecast: -0.0897
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oncolytics Biotech Inc News
New
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic...
THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality
VANCOUVER, British Columbia, Dec. 06, 2025 (GLOBE NEWSWIRE) -- USANewsGroup.comMarket Intelligence Brief – The market is efficient... until it isn't. While the S&P 500 grinds higher on momentum, e...
UPDATE -- The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality
VANCOUVER, British Columbia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- USANewsGroup.comMarket Intelligence Brief – Efficient Market Theory often fails in the small-cap sector. In this space, price discove...
The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality
VANCOUVER, British Columbia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- USANewsGroup.comMarket Intelligence Brief – Efficient Market Theory often fails in the small-cap sector. In this space, price discove...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
